I启明创投、高瓴资本支持，这家药企第三次冲刺上市！

Core Viewpoint - Aikobio has submitted its prospectus for a third attempt to list on the Hong Kong Stock Exchange after previous unsuccessful attempts in 2021 and 2023, with no commercialized products and a post-investment valuation of 4.69 billion yuan [1][2]. Company Overview - Aikobio, founded in 2013, is a biopharmaceutical company focused on developing therapies for respiratory and pediatric diseases [2][3]. - The company has developed six candidate drugs, including its core product Qiruisuo Wei, which is in the New Drug Application (NDA) stage targeting respiratory syncytial virus (RSV) infections [3][4]. Financial Performance - Aikobio reported revenues of 6.7 million yuan in 2023, with losses of approximately 270 million yuan, 197 million yuan, and 104 million yuan for the years 2023, 2024, and the first half of 2025, respectively [4][6]. - The company has not yet achieved profitability and has incurred significant research and development costs of approximately 216 million yuan, 165 million yuan, and 86.14 million yuan during the same period [6]. Cash Position - As of June 30, 2025, Aikobio held cash and cash equivalents of 96.74 million yuan, which may be insufficient to sustain a year of research and development operations at the current expenditure rate [7]. Ownership and Valuation - Aikobio's post-investment valuation stands at 4.69 billion yuan, with significant shareholders including Qiming Venture Partners and Hillhouse Capital [8][10]. - The actual controller of Aikobio, Jim Zhen Wu, holds approximately 25.17% of the company's shares and has extensive experience in drug development [8][9].